Table 1.
Clinicopathologic characteristics of 51 patients according to DTC status after NAC.
| DTC- | % | DTC+ | % | Total | % | p value* | |
|---|---|---|---|---|---|---|---|
| Menopausal status (n=47) | 0.1884 | ||||||
| Post | 11 | 61.1 | 7 | 38.9 | 18 | 38.3 | |
| Pre | 12 | 41.4 | 17 | 58.6 | 29 | 61.7 | |
| Tumor size (n=49) | 0.5604 | ||||||
| T1 and T2 | 20 | 55.6 | 16 | 44.4 | 36 | 73.5 | |
| T3 and T4 | 6 | 46.2 | 7 | 53.8 | 13 | 26.5 | |
| Nodal status (n=48) | 0.7904 | ||||||
| Node-negative | 14 | 53.8 | 12 | 46.2 | 26 | 54.2 | |
| Node-positive | 11 | 50.0 | 11 | 50.0 | 22 | 45.8 | |
| Subtype | 1.0000 | ||||||
| HER2+ | 9 | 52.9 | 8 | 47.1 | 17 | 33.3 | |
| HR+HER2- | 9 | 52.9 | 8 | 47.1 | 17 | 33.3 | |
| Triple negative | 9 | 52.9 | 8 | 47.1 | 17 | 33.3 | |
| MammaPrint | 0.6678 | ||||||
| High 1 | 13 | 50.0 | 13 | 50.0 | 26 | 51.0 | |
| High 2 | 14 | 56.0 | 11 | 44.0 | 25 | 49.0 | |
| Race | 0.0056 | ||||||
| Non-white | 1 | 11.1 | 8 | 88.9 | 9 | 17.6 | |
| White | 26 | 61.9 | 16 | 38.1 | 42 | 82.4 | |
| Pathological complete response | 0.1658 | ||||||
| Yes | 13 | 65.0 | 7 | 35.0 | 20 | 39.2 | |
| No | 14 | 45.2 | 17 | 54.8 | 31 | 60.8 | |
| RCB class | 0.1138 | ||||||
| 0 | 13 | 65.0 | 7 | 35.0 | 20 | 74.1 | |
| I | 5 | 71.4 | 2 | 28.6 | 7 | ||
| II | 5 | 29.4 | 12 | 70.6 | 17 | ||
| III | 4 | 57.1 | 3 | 42.9 | 7 | 25.9 | |
| RCB class (binary) | 0.0373 | ||||||
| 0 and I | 18 | 66.7 | 9 | 33.3 | 27 | 52.9 | |
| II and III | 9 | 37.5 | 15 | 62.5 | 24 | 47.1 | |
| RCB index | 0.1516 | ||||||
| mean (range) | 0.5 | 0–3.8 | 1.6 | 0–3.4 | |||
| Age | 0.0239 | ||||||
| mean (range) [Years] | 50.1 | 28–72 | 43.4 | 26–64 | |||
| Longest tumor diameter by MRI (pretreatment) | 0.0319 | ||||||
| mean and range [cm] | 4.1 | 1.8–8.5 | 5.6 | 1.5–12.9 |
*
For continuous clinicopathologic variables (age and tumor size), association with DTC-positivity was assessed using a t-test. For categorical variables, association with DTC-positivity was assessed using a Chi-squared test. RCB-residual cancer burden.